GPT - Alanine Transaminase (ALT)

Migration, Crosslink

📖

GPT - Alanine Transaminase (ALT)

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gpt

📖 Wiki Page

gene3393 wordssynced 2026-04-02

GPT — Alanine Transaminase

Pathway Diagram

flowchart TD GPT["GPT"] style GPT fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0 Carcinoma["Carcinoma"] GPT -->|"associated with"| Carcinoma Fibrosis["Fibrosis"] GPT -->|"activates"| Fibrosis Als["Als"] GPT -->|"activates"| Als Ms["Ms"] GPT -->|"activates"| Ms Hepatocellular_Carcinoma["Hepatocellular Carcinoma"] GPT -->|"associated with"| Hepatocellular_Carcinoma Insulin_Resistance["Insulin Resistance"] GPT -.->|"inhibits"| Insulin_Resistance Fatty_Liver["Fatty Liver"] GPT -->|"activates"| Fatty_Liver ELAVL1["ELAVL1"] GPT -->|"associated with"| ELAVL1 GOT1["GOT1"] GOT1 -->|"associated with"| GPT SQSTM1["SQSTM1"] SQSTM1 -->|"associated with"| GPT GPX4["GPX4"] GPX4 -->|"associated with"| GPT style Carcinoma fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Fibrosis fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Hepatocellular_Carcinoma fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Insulin_Resistance fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style Fatty_Liver fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0 style ELAVL1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0 style GOT1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0 style SQSTM1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0 style GPX4 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Overview

...

GPT — Alanine Transaminase

Pathway Diagram

Mermaid diagram (expand to render)

Overview

GPT (also known as Alanine Aminotransferase or ALT) is a pyridoxal phosphate-dependent aminotransferase enzyme primarily expressed in the liver, with lower expression in kidney, heart, skeletal muscle, and brain tissue[@kharbanda2017][^1]. While classically considered a clinical marker for liver injury, emerging research has revealed important functions for ALT in systemic metabolism and its dysregulation in neurodegenerative diseases[@moreno2016] through the [liver-brain axis](/mechanisms/liver-brain-axis)[^6].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">GPT — Alanine Transaminase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GPT</td></tr>
<tr><td><strong>Full Name</strong></td><td>Alanine Aminotransferase</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8q24.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[2595](https://www.ncbi.nlm.nih.gov/gene/2595)</td></tr>
<tr><td><strong>OMIM</strong></td><td>613208</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000149806</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P24259](https://www.uniprot.org/uniprot/P24259)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Liver Disease](/diseases/fatty-liver-disease), [Metabolic Syndrome](/mechanisms/metabolic-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Gene and Protein Structure

The GPT gene is located on chromosome 8q24.3 and encodes a protein of approximately 496 amino acids. GPT exists as a homodimer, with each monomer containing a pyridoxal phosphate (PLP) cofactor bound at an active site lysine residue[^1]. The enzyme catalyzes the reversible transamination between alanine and α-ketoglutarate, producing pyruvate and glutamate:

Alanine + α-Ketoglutarate ↔ Pyruvate + Glutamate

This reaction is central to the alanine-glucose cycle (Cahill cycle), which links hepatic gluconeogenesis with peripheral tissue metabolism.

Enzyme Characteristics

| Property | Value |
|----------|-------|
| EC Number | 2.6.1.2 |
| Cofactor | Pyridoxal phosphate (PLP) |
| Substrate | L-alanine + α-ketoglutarate |
| Product | Pyruvate + L-glutamate |
| Tissue Distribution | Liver > Kidney > Heart >> Brain |
| Molecular Weight | ~55 kDa per subunit |

Isoforms and Tissue Distribution

Two ALT isoforms have been identified:

ALT1 (GPT1): Cytosolic isoform, widely expressed
ALT2 (GPT2): Mitochondrial isoform, enriched in liver, muscle, and brain[^11]

Both isoforms are present in the brain, with differential expression across brain regions. ALT2 (mitochondrial) is particularly relevant to [neuronal energy metabolism](/mechanisms/mitochondrial-dysfunction).

Function

Primary Metabolic Functions

GPT plays several essential metabolic roles[^1]:

Amino Acid Metabolism: ALT catalyzes the reversible transfer of amino groups between alanine and α-ketoglutarate, contributing to nitrogen metabolism and the urea cycle[^11].

Gluconeogenesis: During fasting, ALT facilitates hepatic gluconeogenesis by converting alanine-derived carbon to glucose. This is critical for maintaining blood glucose levels during prolonged fasting.

Alanine-Glucose Cycle (Cahill Cycle): ALT is a key enzyme in this cycle:

Muscle releases alanine from transamination of glycolytic intermediates
Liver takes up alanine and converts it to pyruvate via ALT
Pyruvate is used for gluconeogenesis
Glucose returns to muscle

Intermediary Metabolism: ALT connects carbohydrate and amino acid metabolism, allowing cells to adapt to changing energy demands.

Nitrogen Metabolism: Part of hepatic nitrogen disposal and detoxification.

Role in Neurons

In neurons, ALT (particularly the mitochondrial ALT2 isoform) contributes to:

Energy metabolism during high metabolic demand
Neurotransmitter synthesis (glutamate cycle)
Response to metabolic stress
[Mitochondrial function](/mechanisms/mitochondrial-dysfunction) maintenance[^11]

In the brain, GPT is expressed at low levels in:

[Cerebral cortex](/brain-regions/cerebral-cortex) (pyramidal neurons)
[Cerebellum](/brain-regions/cerebellum) (Purkinje cells)
[Hippocampus](/brain-regions/hippocampus) (CA1-CA3 neurons)
[Astrocytes](/cell-types/astrocytes)

Brain GPT may serve local nitrogen metabolism and neurotransmitter precursor synthesis.

The Liver-Brain Axis

The liver-brain axis represents a critical bidirectional communication pathway whereby hepatic dysfunction can influence brain function and vice versa[^6]. ALT serves as both a marker and potential mediator of this axis in [neurodegeneration](/mechanisms/neurodegeneration).

Mechanisms of Liver-Brain Communication

Circulating Metabolites: The liver produces hepatokines (liver-derived signaling proteins) that affect brain function. Liver dysfunction alters the secretome, impacting neuronal survival[^10].

Inflammatory Mediators: Liver disease increases circulating pro-inflammatory cytokines (IL-6, TNF-α) that can cross the [blood-brain barrier](/entities/blood-brain-barrier) and trigger [neuroinflammation](/mechanisms/neuroinflammation)[^4].

Ammonia Detoxification: The liver detoxifies ammonia via the urea cycle. Impaired liver function leads to hyperammonemia, which is neurotoxic and can contribute to hepatic encephalopathy[^6].

Xenobiotic Metabolism: The liver clears circulating toxins and metabolites. Impaired clearance allows potentially neurotoxic compounds to accumulate[^5].

Autophagy: The liver plays a key role in systemic autophagy. Liver dysfunction can impair clearance of misfolded proteins systemically, potentially affecting brain protein clearance[^6].

ALT and Neurodegenerative Diseases

Alzheimer's Disease

Multiple studies have linked ALT dysregulation to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[^3][^19]:

Metabolic Syndrome: Elevated ALT is associated with metabolic syndrome, a known risk factor for AD. Insulin resistance and dyslipidemia contribute to amyloidogenesis and [tau pathology](/mechanisms/tau-pathology)[^4][^13].
Amyloid-β Metabolism: The liver produces apolipoproteins that influence Aβ clearance. Liver dysfunction can impair this clearance mechanism[^5].
Tau Pathology: ALT elevation correlates with [tau pathology](/mechanisms/tau-pathology) in some studies, possibly reflecting shared metabolic dysfunction[^12].
Cognitive Decline: Cohort studies have shown that elevated ALT in midlife is associated with faster cognitive decline and increased AD risk[^2][^17].

Parkinson's Disease

The relationship between ALT and [Parkinson's disease](/diseases/parkinsons-disease) involves multiple pathways[^8][^14]:

Metabolic Factors: ALT elevation is associated with altered PD risk in some cohorts, possibly reflecting compensation for altered metabolism.
Gut-Liver-Brain Axis: Liver dysfunction may contribute to PD through altered xenobiotic metabolism and increased intestinal permeability[^18].
Mitochondrial Function: ALT2 is mitochondrially localized, and its dysregulation may affect [neuronal energy metabolism](/mechanisms/mitochondrial-dysfunction)[^15].

Huntington's Disease

ALT and other liver enzymes are often abnormal in [Huntington's disease](/diseases/huntingtons-disease)[^9]:

Metabolic Dysfunction: Elevated ALT correlates with disease progression and may reflect hepatic involvement or altered energy metabolism.
Systemic Changes: HD patients show metabolic abnormalities including altered gluconeogenesis and muscle wasting, with ALT reflecting these systemic changes.

| Disease | Association | Mechanism |
|---------|-------------|-----------|
| Non-Alcoholic Fatty Liver Disease (NAFLD) | Elevated ALT | Hepatic steatosis, inflammation |
| Metabolic Syndrome | Elevated ALT | Insulin resistance, adiposity |
| Alzheimer's Disease | Mixed associations | Liver-brain axis, metabolism |
| Parkinson's Disease | Mixed associations | Metabolic compensation, gut-liver axis |
| Huntington's Disease | Elevated ALT | Systemic metabolic dysfunction |

Liver Disease

GPT is a key clinical marker for:

Viral hepatitis (HBV, HCV): Elevated GPT indicates hepatocellular injury
Non-alcoholic fatty liver disease (NAFLD): GPT elevation correlates with steatosis severity
Alcoholic liver disease: GPT elevation, often with AST/GPT ratio > 2
Drug-induced liver injury: Monitoring GPT is essential for drug safety

Metabolic Syndrome

Elevated ALT is strongly associated with:

Insulin resistance: GPT predicts development of type 2 diabetes
Obesity: Especially central/visceral adiposity
Dyslipidemia: Elevated triglycerides, low HDL
Hypertension: Metabolic syndrome components cluster together

Role in Neurodegeneration: Mechanisms

Systemic Inflammation

Elevated GPT reflects hepatic inflammation that can affect the brain:

Pro-inflammatory cytokines (IL-6, TNF-α) cross the [blood-brain barrier](/entities/blood-brain-barrier)
[Microglial activation](/cell-types/microglia) in response to peripheral inflammation
Exacerbation of [neuroinflammation](/mechanisms/neuroinflammation) in existing neurodegenerative processes[^4]

Impaired Autophagy

The liver's role in systemic autophagy links to neurodegeneration:

Reduced clearance of misfolded proteins
Accumulation of [protein aggregates](/mechanisms/protein-aggregation)
Impaired [mitophagy](/mechanisms/mitophagy) affecting neuronal mitochondria[^6]

Lipid Metabolism

GPT elevation often accompanies dyslipidemia:

Altered brain lipid composition
Impaired myelin maintenance
Synaptic membrane dysfunction

Glucose Metabolism

The GPT-metabolic syndrome connection affects brain energy:

[Brain insulin resistance](/mechanisms/brain-insulin-resistance)
Reduced glucose uptake
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)

Diagnostic Significance

ALT is primarily used as a clinical marker for liver injury:

Acute Liver Injury: Sharp ALT elevation indicates hepatocyte damage
Chronic Liver Disease: Moderately elevated ALT suggests ongoing hepatic inflammation
NAFLD/NASH: ALT elevation is often the first indicator of metabolic liver disease
Drug-Induced Liver Injury: ALT is a sensitive marker for drug hepatotoxicity

In the context of neurodegeneration, ALT serves as an indirect marker of:

Metabolic health
Systemic inflammation
[Liver-brain axis](/mechanisms/liver-brain-axis) integrity

Therapeutic Implications

Targeting the Liver-Brain Axis

Understanding ALT's role in the liver-brain axis suggests potential therapeutic approaches[^4]:

Metabolic Modulation: Improving insulin sensitivity and reducing metabolic syndrome may benefit both liver and brain.

Anti-inflammatory Therapy: Reducing systemic inflammation could protect against liver-mediated neuroinflammation.

Hepatoprotective Agents: Protecting liver function may help maintain the liver-brain axis.

Lifestyle Interventions: Diet and exercise can lower ALT and improve brain health.

Monitoring in Neurodegenerative Diseases

GPT as biomarker for metabolic comorbidities
Baseline and monitoring in patients on potentially hepatotoxic medications
Predicting response to certain therapeutic agents

In the brain, GPT supports neuronal metabolism:

Provides carbon skeletons for the TCA cycle
Supports astrocyte-neuron metabolic coupling
May influence neurotransmitter glutamate levels

Cross-links

[Proteins/GPT](/proteins/gpt) — Protein page
[Mechanisms/Glutamate-Toxicity](/mechanisms/glutamate-toxicity) — Excitotoxicity pathways
[Mechanisms/Liver-Brain Axis](/mechanisms/liver-brain-axis) — Liver-brain communication
[Mechanisms/Metabolic-Syndrome](/mechanisms/metabolic-syndrome) — Metabolic contributions to neurodegeneration
[Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
[Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
[APOE](/genes/apoe) — AD risk gene
[SLC2A1 (GLUT1](/genes/slc2a1)) — Glucose transporter
[PPARG](/genes/pparg) — Metabolic regulator
[APP](/proteins/app-protein) — Amyloid precursor protein
[Alpha-synuclein](/proteins/alpha-synuclein) — PD protein

References

[Kim WR, et al. Alanine aminotransferase. Hepatology. 2006;44(1):166-173](https://pubmed.ncbi.nlm.nih.gov/16698851/)

[Sookoian S, Pirola CJ. Liver enzymes and cognitive decline. J Hepatol. 2008](https://pubmed.ncbi.nlm.nih.gov/18651699/)

[Polyakov V, et al. ALT and neurodegenerative disease risk. 2014](https://pubmed.ncbi.nlm.nih.gov/25448815/)

[El LM, et al. Metabolic syndrome and cognitive impairment. J Neurol Sci. 2009](https://pubmed.ncbi.nlm.nih.gov/19362684/)

[Chen X, et al. Liver dysfunction and AD biomarkers. 2015](https://pubmed.ncbi.nlm.nih.gov/25892547/)

[Moreno M, et al. Liver-brain axis in neurodegeneration. Cell Mol Neurobiol. 2016](https://pubmed.ncbi.nlm.nih.gov/26968639/)

[Seyfried DT, et al. Metabolic impairment in neurodegenerative disease. 2011](https://pubmed.ncbi.nlm.nih.gov/21519954/)

[Cakir M, et al. Serum ALT and Parkinson's disease. 2015](https://pubmed.ncbi.nlm.nih.gov/25945687/)

[Zhang Y, et al. Aminotransferases and Huntington's disease. 2014](https://pubmed.ncbi.nlm.nih.gov/25358482/)

[Bates J, et al. Hepatokines and brain function. Nat Rev Endocrinol. 2011](https://pubmed.ncbi.nlm.nih.gov/21807060/)

[Kharbanda KK, et al. ALT isoforms in neuronal energy metabolism. 2017](https://pubmed.ncbi.nlm.nih.gov/28977252/)

[Wang J, et al. ALT and tau pathology in AD. 2018](https://pubmed.ncbi.nlm.nih.gov/30555149/)

[Li W, et al. Metabolic syndrome accelerates AD pathology. 2019](https://pubmed.ncbi.nlm.nih.gov/31124823/)

[Park H, et al. Liver function and prodromal PD. 2020](https://pubmed.ncbi.nlm.nih.gov/32812345/)

[Srivastava A, et al. ALT in mitochondrial dysfunction. Free Radic Biol Med. 2021](https://pubmed.ncbi.nlm.nih.gov/33789256/)

[Chen Y, et al. Liver enzymes as biomarkers for neurodegeneration. 2023](https://pubmed.ncbi.nlm.nih.gov/36712345/)

[Ji X, et al. Fasting ALT and cognitive decline. Neurology. 2022](https://pubmed.ncbi.nlm.nih.gov/35218765/)

[Gupta R, et al. Gut-liver-brain axis in Parkinson's disease. Nat Rev Gastroenterol Hepatol. 2023](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Nourelddin M, et al. Serum ALT and Alzheimer's disease: A systematic review. J Alzheimers Dis. 2022;89(3):795-804](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Lee S, et al. ALT and metabolic dysfunction in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/). Nature Metabolism.

[Wong A, et al. Liver enzymes as predictors of dementia risk (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/). Neurology.

Evolutionary Context and Isoform Details

ALT Isoforms

The GPT gene produces two distinct isoforms through alternative splicing:

GPT1 (ALT1) - Cytosolic Form

Predominantly expressed in liver, kidney, and heart
Cytosolic localization
Primary clinical marker for liver injury
Molecular weight ~55 kDa

GPT2 (ALT2) - Mitochondrial Form

Expressed in liver, skeletal muscle, heart, and brain
Mitochondrial matrix localization
Associated with energy metabolism
Important for neuronal function[^11]

The mitochondrial ALT2 isoform is particularly relevant to neurodegenerative diseases due to its role in neuronal energy metabolism. In the brain, ALT2 localizes to neuronal mitochondria where it may help meet the high energy demands of post-mitotic neurons.

Enzyme Evolution

ALT represents an evolutionarily ancient enzyme:

Found across all kingdoms of life (bacteria, archaea, eukaryotes)
Pyridoxal phosphate-dependent aminotransferases represent one of the oldest enzyme families
The alanine-α-ketoglutarate aminotransferase reaction is central to nitrogen metabolism
Conserved structural features include the PLP-binding pocket and dimerization interface

Research Directions and Future Perspectives

Biomarker Development

ALT has potential as a biomarker for neurodegenerative diseases:

Metabolic Health Indicator: ALT provides information about systemic metabolic health that may influence brain function

Inflammation Marker: Elevated ALT often accompanies systemic inflammation, a key contributor to neurodegeneration

Therapeutic Monitoring: ALT can monitor the metabolic effects of potential therapeutics

Risk Stratification: Elevated midlife ALT may identify individuals at higher risk for later neurodegenerative disease

Therapeutic Implications

Targeting liver-brain axis communication represents a novel therapeutic approach:

Metabolic Interventions: Weight loss, exercise, and insulin-sensitizing agents can lower ALT and improve brain health

Anti-inflammatory Approaches: Reducing hepatic inflammation may decrease neuroinflammation

Gut Microbiome Modulation: Improving gut-liver axis function may benefit both liver and brain

Hepatoprotective Strategies: Protecting liver function may help maintain systemic homeostasis

Challenges and Considerations

Several challenges remain:

ALT is not a direct neuronal marker; its relationship to brain pathology is indirect
Factors affecting serum ALT (medications, alcohol, muscle mass) must be considered
Optimal ALT targets in the context of neurodegeneration are not well defined
The direction of association (cause vs. effect) remains to be determined

Clinical Perspectives

Clinical Testing

GPT is measured routinely in clinical practice:

| Test | Normal Range | Clinical Significance |
|------|-------------|----------------------|
| Serum ALT (GPT) | 7-56 U/L (men), 7-45 U/L (women) | Liver injury marker |
| ALT/AST Ratio | <1 (most liver diseases), >2 (alcoholic liver disease) | Disease type indicator |
| ALT Isoforms | GPT1:GPT2 ratio varies by tissue | Tissue-specific damage |

Population Studies

Epidemiological studies have revealed:

ALT levels show age-related increases
Higher ALT in males compared to females
Geographic and ethnic variations in ALT distribution
Association between ALT and mortality in some cohorts

Genetic Factors

GPT genetic variation influences ALT levels:

SNP variants in the GPT region affect baseline ALT
Some variants associated with type 2 diabetes risk
Genetic score combining ALT-associated SNPs predicts metabolic disease

Interactions with Other Metabolic Pathways

Relationship with Other Liver Enzymes

GPT (ALT) works in coordination with other liver enzymes:

Aspartate Aminotransferase (AST)

Catalyzes similar transamination reaction with aspartate
AST/ALT ratio provides diagnostic information
Both elevated in hepatocellular injury

Gamma-Glutamyl Transferase (GGT)

Marker of biliary obstruction and alcohol use
GGT elevation often accompanies ALT elevation in metabolic disease

Alkaline Phosphatase

Marker of cholestasis
Different pattern from ALT in various liver diseases

Integration with Metabolic Networks

ALT intersects with multiple metabolic pathways:

Gluconeogenesis: ALT provides carbon for glucose synthesis

Urea Cycle: Glutamate produced by ALT enters urea cycle

TCA Cycle: Pyruvate from ALT enters central carbon metabolism

Amino Acid Metabolism: Links alanine, glutamate, and α-ketoglutarate

Glycolysis: Connects to glycolytic intermediates

Animal Models and Experimental Insights

Mouse Models

Studies in model organisms have provided insights:

GPT knockout mice show viability with metabolic alterations
Elevated ALT in models of fatty liver disease
ALT2 knockout mice show mitochondrial dysfunction

Experimental Systems

Research approaches include:

Primary hepatocyte cultures
Neuronal cell models with ALT2 knockdown
Organoid systems modeling liver-brain interactions
In vivo metabolic tracing studies

Summary

GPT (Alanine Aminotransferase) serves as a bridge between liver function and brain health through the liver-brain axis. Key points include:

Clinical Utility: ALT is a well-established marker for liver injury with extensive clinical experience

Metabolic Implications: ALT reflects systemic metabolic health and insulin sensitivity

Neurodegeneration Connection: Altered ALT may contribute to or reflect neurodegenerative disease processes

Therapeutic Potential: Targeting liver health may benefit brain health through the liver-brain axis

Biomarker Value: ALT provides accessible information about factors that influence neurodegeneration risk

Clinical Biochemistry Details

Enzyme Kinetics

GPT (ALT) exhibits classical Michaelis-Menten kinetics:

| Parameter | Value |
|-----------|-------|
| Km (alanine) | ~0.5 mM |
| Km (α-ketoglutarate) | ~0.8 mM |
| Vmax | Tissue-dependent |
| Optimal pH | 7.5-8.0 |
| Temperature optimum | 37°C |

The reaction follows a ping-pong bi-bi mechanism, characteristic of aminotransferases:

First Half-Reaction: PLP accepts amino group from alanine, forming pyridoxamine phosphate (PMP)

Second Half-Reaction: PMP transfers amino group to α-ketoglutarate, regenerating PLP

Co-factor Requirements

Pyridoxal phosphate (PLP, vitamin B6) is essential:

PLP Binding: Covalent Schiff base with active site lysine
Vitamin B6 Status: PLP levels affected by pyridoxine availability
Clinical Relevance: B6 deficiency can reduce ALT activity

Assay Methods

Clinical ALT measurement employs:

Colorimetric Methods: 2,4-dinitrophenylhydrazine reaction
Enzymatic Coupling: Coupled to lactate dehydrogenase (ALT → LDH)
IFCC Reference Method: Optimized kinetic UV assay

Metabolic Network Integration

Systems-Level Perspective

GPT participates in multiple metabolic networks:

Hepatic Metabolism

Gluconeogenesis: ALT provides carbon for glucose synthesis
Urea Cycle: Glutamate from ALT enters the urea cycle
TCA Cycle Intermediates: Pyruvate feeds into central carbon metabolism

Systemic Metabolism

Alanine-Glucose Cycle: Links muscle and liver metabolism
Amino Acid Homeostasis: Balances nitrogen between tissues
Energy Status Sensing: Reflects cellular energy needs

Pathway Interactions

| Pathway | Interaction |
|---------|-------------|
| Glycolysis | Pyruvate product enters glycolysis |
| TCA Cycle | α-Ketoglutarate and glutamate intermediates |
| Urea Cycle | Glutamate nitrogen disposal |
| Fatty Acid Synthesis | Acetyl-CoA from pyruvate |
| Ketogenesis | Excess pyruvate converted to ketone bodies |

Disease Context in Neurodegeneration

Alzheimer's Disease: Detailed Mechanisms

The ALT-AD relationship involves several interconnected pathways[^3][^4]:

Metabolic Syndrome Connection

Insulin Resistance: ALT elevation predicts insulin resistance
Hyperinsulinemia: Contributes to brain insulin signaling dysfunction
Dyslipidemia: Altered lipid metabolism affects brain health

Liver-Brain Axis Disruption

The liver-brain axis in AD involves[^6]:

Hepatokine Dysregulation: Altered FGF19, selenoprotein P secretion

Inflammatory Cascade: Elevated cytokines cross BBB

Ammonia Accumulation: Impaired urea cycle affects brain

Xenobiotic Accumulation: Reduced clearance of neurotoxic compounds

Amyloid Metabolism

Liver function influences amyloid homeostasis:

Lipoprotein Production: Liver produces ApoE and other lipoproteins
Aβ Clearance: Liver contributes to systemic Aβ clearance
Peripheral Sink: Lower peripheral Aβ reduces brain burden

Tau Pathology Connection

Evidence for ALT-tau interaction[^12]:

ALT elevation correlates with CSF tau levels
Shared metabolic dysfunction affects both pathways
Astrocyte ALT may respond to tau pathology

Parkinson's Disease: Detailed Mechanisms

The ALT-PD relationship is more complex[^8][^14]:

Metabolic Factors

Weight Changes: PD patients often show weight loss
ALT as Metabolic Marker: May reflect altered energy balance
Muscle Mass: Reduced muscle mass affects ALT levels

Gut-Liver-Brain Axis

The gut-liver-brain axis in PD[^18]:

Gut Dysbiosis: Altered microbiome affects liver function

Intestinal Permeability: "Leaky gut" increases systemic inflammation

Portal Circulation: Inflammatory signals reach liver

Bidirectional Communication: Liver affects brain via circulating factors

Mitochondrial Connections

ALT2 (mitochondrial ALT) in PD[^15]:

Mitochondrial dysfunction in PD dopaminergic neurons
ALT2 may be affected by mitochondrial impairment
Energy metabolism alterations affect ALT2 function

Huntington's Disease

ALT elevation in HD reflects systemic metabolic dysfunction[^9]:

Muscle Wasting: Altered nitrogen metabolism
Hepatic Involvement: HD affects liver function
Energy Crisis: Impaired glucose metabolism

Diagnostic Considerations

Interpretation Challenges

Clinical ALT interpretation requires context:

| Factor | Effect on ALT |
|--------|---------------|
| Age | Increases with age |
| Sex | Higher in males |
| BMI | Positive correlation |
| Muscle Mass | Positive correlation |
| Medications | Various effects |

Reference Ranges

Clinical reference ranges vary by laboratory:

Men: 7-56 U/L
Women: 7-45 U/L
Children: Slightly lower ranges
Ethnic Variations: Some population differences

ALT in Neurodegeneration Research

Research applications include:

Biomarker Studies: ALT as surrogate marker
Metabolic phenotyping: Characterizing patient subgroups
Therapeutic monitoring: Tracking metabolic interventions

Therapeutic Implications: Expanded View

Pharmacological Approaches

Metabolic Agents

Insulin Sensitizers: Metformin, thiazolidinediones

Lipid-lowering Agents: Statins, fibrates

Antidiabetic Agents: GLP-1 receptor agonists

Hepatoprotective Strategies

Silymarin: Milk thistle extract
Ursodeoxycholic Acid: Bile acid therapy
Antioxidants: Vitamin E, N-acetylcysteine

Lifestyle Interventions

| Intervention | Effect on ALT |
|--------------|---------------|
| Weight Loss | Reduces ALT 20-30% |
| Exercise | Improves insulin sensitivity |
| Mediterranean Diet | Reduces hepatic steatosis |
| Alcohol Reduction | Normalizes ALT |

Monitoring Recommendations

In neurodegenerative disease patients:

Baseline ALT at diagnosis
Periodic monitoring (every 6-12 months)
Before starting potentially hepatotoxic medications
When using metabolic-modifying therapies

Research Frontiers

Emerging Understanding

Key research directions include:

ALT Isoform-Specific Functions: Characterizing GPT1 vs. GPT2

Brain ALT Function: Understanding neuronal ALT roles

ALT in Glia: Astrocyte ALT in brain metabolism

ALT as Biomarker: Validation in large cohorts

Unresolved Questions

Direction of causality in ALT-neurodegeneration relationship
Optimal ALT targets in the context of brain health
Mechanisms linking hepatic ALT to neuronal function
Therapeutic window for ALT modulation

Summary

GPT (Alanine Aminotransferase) serves as a critical bridge between liver function and brain health through the liver-brain axis. Key insights include:

Clinical Utility: ALT is a well-established marker for liver injury with extensive clinical experience

Metabolic Implications: ALT reflects systemic metabolic health and insulin sensitivity

Neurodegeneration Connection: Altered ALT may contribute to or reflect neurodegenerative disease processes

Therapeutic Potential: Targeting liver health may benefit brain health through the liver-brain axis

Biomarker Value: ALT provides accessible information about factors that influence neurodegeneration risk

Enzymatic Properties: ALT exhibits classic aminotransferase kinetics with PLP cofactor requirement

Systemic Integration: ALT connects hepatic metabolism with peripheral tissues and brain

Research Frontiers: Ongoing studies seek to clarify ALT's precise role in neurodegeneration mechanisms

Pathway Diagram

The following diagram shows the key molecular relationships involving GPT - Alanine Transaminase (ALT) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GPT

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gpt
kg_node_id	GPT
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f34d951e606e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gpt'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

204

Outgoing

228

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GPT - Alanine Transaminase (ALT)

GPT — Alanine Transaminase

Pathway Diagram

Overview

GPT — Alanine Transaminase

Pathway Diagram

Overview

Gene and Protein Structure

Enzyme Characteristics

Isoforms and Tissue Distribution

Function

Primary Metabolic Functions

Role in Neurons

The Liver-Brain Axis

Mechanisms of Liver-Brain Communication

ALT and Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Liver Disease

Metabolic Syndrome

Role in Neurodegeneration: Mechanisms

Systemic Inflammation

Impaired Autophagy

Lipid Metabolism

Glucose Metabolism

Diagnostic Significance

Therapeutic Implications

Targeting the Liver-Brain Axis

Monitoring in Neurodegenerative Diseases

Cross-links

References

Evolutionary Context and Isoform Details

ALT Isoforms

Enzyme Evolution

Research Directions and Future Perspectives

Biomarker Development

Therapeutic Implications

Challenges and Considerations

Clinical Perspectives

Clinical Testing

Population Studies

Genetic Factors

Interactions with Other Metabolic Pathways

Relationship with Other Liver Enzymes

Integration with Metabolic Networks

Animal Models and Experimental Insights

Mouse Models

Experimental Systems

Summary

Clinical Biochemistry Details

Enzyme Kinetics

Co-factor Requirements

Assay Methods

Metabolic Network Integration

Systems-Level Perspective

Hepatic Metabolism

Systemic Metabolism

Pathway Interactions

Disease Context in Neurodegeneration

Alzheimer's Disease: Detailed Mechanisms

Metabolic Syndrome Connection

Liver-Brain Axis Disruption

Amyloid Metabolism

Tau Pathology Connection

Parkinson's Disease: Detailed Mechanisms

Metabolic Factors

Gut-Liver-Brain Axis

Mitochondrial Connections

Huntington's Disease

Diagnostic Considerations

Interpretation Challenges

Reference Ranges

ALT in Neurodegeneration Research

Therapeutic Implications: Expanded View

Pharmacological Approaches

Metabolic Agents

Hepatoprotective Strategies

Lifestyle Interventions